• Vaccine Name: prime/boost DC-TRP-2 melanoma vaccine
• Target Pathogen: Cancer
• Target Disease: Cancer
• Vaccine Ontology ID: VO_0007098
• Type: Dendritic cell-based vaccine
• Status: Research
• Preparation: assessing the ability of dendritic cell (DC)-based vaccines to induce a long-lasting tumor-specific CTL response in either prophylactic or therapeutic settings by taking advantage of transplantable and spontaneous mouse tumor models(Ricupito et al., 2013).
• Immunization Route: Intramuscular injection (i.m.)
• Description: This is for Melanoma Cancer. Prime/boost vaccination proved to be of no advantage or even detrimental in therapeutic settings in B16F1 and transgenic adenocarcinoma of the mouse prostate (TRAMP) models, respectively (Ricupito et al., 2013).

Mouse Response

• Vaccine Immune Response Type: VO_0003057
• Immune Response: DC-based vaccine induced a long-lasting CTL response in wild-type mice, and homologous boosting better sustained the pool of central memory T cells, a tight boosting schedule hindered persistence of IFN-γ-competent memory CD8(+) T cells and mice survival in prophylactic settings (Ricupito et al., 2013).